Free Trial
NASDAQ:MNKD

MannKind (MNKD) Stock Price, News & Analysis

MannKind logo
$5.47 +0.12 (+2.24%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$5.48 +0.01 (+0.20%)
As of 06:37 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About MannKind Stock (NASDAQ:MNKD)

Advanced

Key Stats

Today's Range
$5.20
$5.52
50-Day Range
$3.42
$5.76
52-Week Range
$3.38
$7.63
Volume
5.61 million shs
Average Volume
4.64 million shs
Market Capitalization
$1.68 billion
P/E Ratio
49.73
Dividend Yield
N/A
Price Target
$10.86
Consensus Rating
Moderate Buy

Company Overview

MannKind Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
79th Percentile Overall Score

MNKD MarketRank™: 

MannKind scored higher than 79% of companies evaluated by MarketBeat, and ranked 196th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    MannKind has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.

  • Upside Potential

    MannKind has a consensus price target of $10.86, representing about 98.5% upside from its current price of $5.47.

  • Amount of Analyst Coverage

    MannKind has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about MannKind's stock forecast and price target.
  • Earnings Growth

    Earnings for MannKind are expected to grow by 130.00% in the coming year, from $0.10 to $0.23 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of MannKind is 49.73, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 200.35.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of MannKind is 49.73, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 85.78.

  • Read more about MannKind's valuation and earnings.
  • Percentage of Shares Shorted

    6.14% of the float of MannKind has been sold short.
  • Short Interest Ratio / Days to Cover

    MannKind has a short interest ratio ("days to cover") of 4.4.
  • Change versus previous month

    Short interest in MannKind has recently increased by 9.51%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    MannKind does not currently pay a dividend.

  • Dividend Growth

    MannKind does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.14% of the float of MannKind has been sold short.
  • Short Interest Ratio / Days to Cover

    MannKind has a short interest ratio ("days to cover") of 4.4.
  • Change versus previous month

    Short interest in MannKind has recently increased by 9.51%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    MannKind has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for MannKind this week, compared to 7 articles on an average week.
  • Search Interest

    29 people have searched for MNKD on MarketBeat in the last 30 days. This is an increase of 123% compared to the previous 30 days.
  • MarketBeat Follows

    Only 6 people have added MannKind to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, MannKind insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $250,980.00 in company stock.

  • Percentage Held by Insiders

    Only 3.00% of the stock of MannKind is held by insiders.

  • Percentage Held by Institutions

    49.55% of the stock of MannKind is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about MannKind's insider trading history.
Receive MNKD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MannKind and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MNKD Stock News Headlines

MannKind: Durable Cash Engine, Optional Catalysts Pending
MannKind: Durable Cash Engine, Optional Catalysts Pending
This dark force is about to change everything
Something unusual is unfolding inside the Republican Party — from Marjorie Taylor Greene breaking ranks to Ted Cruz calling the White House a “mafia,” and even Trump’s approval rating slipping. But veteran analyst Porter Stansberry says this isn’t really about politics at all. It’s part of a much larger shift he calls The Final Displacement — a historic economic and social realignment already impacting millions of Americans. His new documentary explains what’s driving it and how to prepare before it accelerates further.tc pixel
MannKind (NASDAQ:MNKD) Earns Buy Rating from HC Wainwright
MannKind's Afrezza under supplemental FDA review
See More Headlines

MNKD Stock Analysis - Frequently Asked Questions

MannKind's stock was trading at $6.43 at the start of the year. Since then, MNKD shares have decreased by 14.9% and is now trading at $5.47.

MannKind Corporation (NASDAQ:MNKD) announced its quarterly earnings results on Wednesday, August, 6th. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.01. The firm's revenue was up 5.7% on a year-over-year basis.
Read the conference call transcript
.

MannKind's top institutional shareholders include 180 Wealth Advisors LLC (0.94%), Aaron Wealth Advisors LLC (0.06%), Voya Investment Management LLC (0.02%) and CWM LLC (0.01%). Insiders that own company stock include Michael Castagna, Stuart A Tross, David Thomson and Steven B Binder.
View institutional ownership trends
.

Shares of MNKD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that MannKind investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Bausch Health Cos (BHC), Intel (INTC) and Netflix (NFLX).

Company Calendar

Last Earnings
8/06/2025
Today
10/19/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MNKD
CIK
899460
Employees
400
Year Founded
1991

Price Target and Rating

High Price Target
$15.00
Low Price Target
$8.00
Potential Upside/Downside
+98.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.11
Trailing P/E Ratio
49.73
Forward P/E Ratio
54.70
P/E Growth
N/A
Net Income
$27.59 million
Net Margins
10.87%
Pretax Margin
11.89%
Return on Equity
-32.60%
Return on Assets
7.81%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.50
Quick Ratio
2.24

Sales & Book Value

Annual Sales
$301.74 million
Price / Sales
5.56
Cash Flow
$0.14 per share
Price / Cash Flow
39.41
Book Value
($0.29) per share
Price / Book
-18.86

Miscellaneous

Outstanding Shares
306,828,000
Free Float
298,544,000
Market Cap
$1.68 billion
Optionable
Optionable
Beta
1.08

Social Links

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:MNKD) was last updated on 10/20/2025 by MarketBeat.com Staff
From Our Partners